---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-001263"
form_type: "8-K/A"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:13:28.959944+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tivic Health files Scorpius audited financials; FY2024 net loss $32.8M on $6.2M revenue

## Summary
- Scorpius FY2024 revenue $6.24M, net loss $32.8M; auditor BDO flags going-concern doubt due to recurring losses.
- Scorpius total assets $39.2M, total liabilities $37.5M, stockholders' equity $1.7M at Dec 31, 2024.
- Tivic sub Velocity Bioworks acquired all Scorpius assets on Dec 9, 2025, assuming no pre-closing liabilities.
- Pro forma combined financials filed for Sep 30, 2025 and FY2024; combined company impact not quantified.

## SEC filing metadata
- accession: 0001683168-26-001263
- form_type: 8-K/A
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826001263/0001683168-26-001263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826001263/tivic_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-001263
- JSON: https://secwatch.observer/filing/0001683168-26-001263.json
- Plain text: https://secwatch.observer/filing/0001683168-26-001263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.